Key points are not available for this paper at this time.
Purpose: To evaluate the safety and effectiveness of combining 3 % diquafosol tetrasodium (DQS) with conventional treatment in addressing dry eye disease (DED). Methods: A comprehensive search was conducted in databases, including CNKI, VIP, WANFANG, CBM, DUXIU, PubMed, Embase, Cochrane, Web of Science, Ovid MEDLINE, Scopus, and ProQuest up to June 5, 2023. Thirteen relevant randomized controlled trials (RCTs) were included in the analysis. Odds ratios (ORs) were used for binary categorical variables, and standardized mean difference (SMD) was employed for continuous variables and presented with 95 % confidence intervals (CI). Publication bias was assessed using funnel plot diagrams and the Egger test. Results: Combined treatment with 3 % DQS had significantly better efficacy than control group (that received conventional treatment alone) in improving clinical efficacy, prolonging tear film break-up time, increasing tear secretion volume, and reducing corneal fluorescent staining (p < 0.05). Furthermore, the treatment demonstrated a favorable safety profile. Conclusion: In the management of dry eye disease, the inclusion of 3 % DQS displays better therapeutic effects and safety when compared to other alternative approaches. This study underscores the potential of DQS as a promising intervention for addressing the complex pathogenesis of DED. However, its long-term effectiveness and safety still need to be further evaluated.
Yang et al. (Fri,) studied this question.